Approved with
change to the race/ethnicity question.
Inventory as of this Action
Requested
Previously Approved
09/30/2004
09/30/2004
957
0
0
322
0
0
0
0
0
The Waiver Program permits qualifying
physicians to prescribe and dispense buprenorphine, a schedule III
narcotic drug recently approved by the FDA for the treatment of
opiate addiction. The Drug Abuse Treatment Act specifies that the
Secretary of the Department of Health and Human Services make a
determination of whether: 1) treatments provided under the Waiver
Program have been effective forms of maintenance treatment and
detoxification treatment in clinical setting; 2) the Waiver Program
has significantly increased (relative to the beginning of such
period) the availability of maintenance treatment
and..........
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.